VOR Vor Biopharma

Vor Biopharma Announces Participation at Cowen 41st Annual Health Care Conference

Vor Biopharma Announces Participation at Cowen 41st Annual Health Care Conference

CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Company will be participating in the Cowen 41st Annual Health Care Conference, which will take place virtually on March 1-4, 2021. Robert Ang, MBBS, MBA, Vor’s President and Chief Executive Officer, and Nathan Jorgensen, PhD, Chief Financial Officer, are scheduled to present on Thursday, March 4, 2021, at 1:30 p.m. E.T.

About Vor Biopharma

Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies. By removing biologically redundant proteins from eHSCs, we design these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancerous cells while sparing healthy cells.

Contacts:

Investor:

Constantine Davides, CFA

Westwicke



Media:

Mary Carmichael

Ten Bridge Communications





EN
01/03/2021

Underlying

VORVor Biopharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vor Biopharma

 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Mic...

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors - New board members bring decades of experience in company building, corporate strategy, commercialization, and business development CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Alexander (Bo) Cumbo and Michel Detheux, Ph.D., to its Board of Directors, effective July 16, 2025. Alexander (Bo) Cumbo currently serves as Presiden...

July 21, 2025 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as of July 17, 2025, the Compensation Committee of the Board of Directors granted Qing Zuraw, M.D., the Company’s Chief Development Officer, 4,373,040 stock options and 937,080 restricted stock units (“RSUs”) in connection with the commencement of her employment. The foregoing stock option and RSU awards were granted as a mate...

July 18, 2025 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer Dr. Zuraw led clinical development of telitacicept across MG, Sjögren’s, SLE, and RA at RemeGen, resulting in multiple regulatory approvals in China; brings deep U.S. and global development experience to support Vor Bio’s new development focus and execution of late-stage programs CAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Qing Zuraw, M.D., M.P.H., M.B.A., as Chief Devel...

July 17, 2025 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Fina...

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer Mr. Mahatme brings decades of experience in strategic finance, capital formation, and operational leadership to support company’s transformation and growth in autoimmune disease CAMBRIDGE, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Sandy Mahatme as Chief Financial Officer and Chief Business Officer, effective July 9, 2025. Mr. Mahatme...

July 10, 2025 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as of June 26, 2025, the Board of Directors granted Jean-Paul Kress, the Company’s Chief Executive Officer, an option to purchase 83,296,638 shares of Vor Bio’s common stock in connection with the commencement of his employment. The foregoing stock option was granted as a material inducement to employment with Vor Bio in accord...

July 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch